Supplementary Figure S7 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas
Abstract
Figure S7. The brigatinib+INK128 combination promotes caspase-3/7 activation, indicative of apoptosis.
Fields of Study & Subjects
Meningioma and schwannoma management
Neurofibromatosis and Schwannoma Cases
PI3K/AKT/mTOR signaling in cancer
Publication details
- Publication date
- 27 January 2026